It gets a little complicated, but essentially, BPA/BPS cause changes in a specific microRNA that controls GLP-1 levels
Literature context is not product-claim evidence because published studies evaluate specific compounds, models, and methods under defined research conditions
When taken as an injection or intravenous drip, it bypasses the digestive system and enters the bloodstream directly
Potential reasons for this include: (1) 79% of our patients used a GLP-1 RA for an indication of diabetes rather than weight management, and (2) interactions with breast cancer treatments such as chemotherapy, chemotherapy supportive medications such as steroids, and/or endocrine therapy, which exacerbate metabolic dysfunction and contribute to weight gain, may attenuate weight loss with a GLP-1 RA
After your last injection, clinically relevant levels persist for three to five weeks